Unfractionated heparin is a blood product mainly found in horses that is used to treat hemophilia A and B. It is commonly known as unfractionated heparin. As a blood product it is normally a complex glycosaminoglycan that is very tough to break down. In this case, however, it is broken down into many molecules.
Unfractionated heparin is often used in the treatment for sickle cell disease and anemia in patients with hematological conditions. Unfractionated heparin (UVH) has been shown to increase the activity of neutrophils, Thymus Gland, and Monocytes. It is shown to protect against infections in sickle cell disease patients. It also seems to be useful for both reducing the risk of thrombosis in acute-care settings and reducing the intensity of bleeding. Also in patients with anemia and dialysis it seems to have a positive effect. Unfractionated heparin (UVH) has been compared in patients with anemia, dialysis, and chronic heart failure and showed a significant improvement in outcome when compared with the control group.
Recently, unfractionated heparin was found to have its own unique biological properties. These unique biological properties are known to be important in the fight against infectious diseases. These properties are known to have profound effects on the immune response and on the innate and adaptive immune system. In particular, it has been shown that UVH has potent immunosuppressive, anti-viral, anti-bacterial, anti-fungal, and anti-inflammatory properties.
Unfractionated heparin is considered the better alternative of the synthetic active ingredients in its pure state due to its anticoagulant effect. It successfully reduces blood clots and prevents the formation of Deep Vein Thrombosis (DVT) in patients with severe atherosclerotic disease. Although, it shows less effects in patients with mild atherosclerosis. Unfractionated heparin is useful as a blood thinner and as a vasodilator. It has also shown benefits in patients with moderate benign intracranial hypertension and in those who underwent surgical implantation of the anticoagulant effect of heparin.
Unfractionated heparin is a safe and easy to use blood thinning agent for the treatment of patients with moderate to severe heart failure due to various cardio-related issues like myocardial infarction, unstable angina and heart failure due to hemodialysis. Unfractionated heparin has been shown to significantly improve survival in patients with myocardial infarction and stable angina and to prolong survival in patients with intermittent claudication. Unfractionated heparin has also been found to reduce peripheral blood clotting in patients with acute coronary syndromes and dysfunctional vena cava after pericardial reconstruction in patients with hemodynamics. Furthermore, it shows benefits in patients with dysfunctional venous reflux, acute cholecystitis, rheumatoid arthritis, and rheumatic fever.
Unfractionated heparin is usually formulated as a liposome. The preparation is mixed with a small amount of purified water. The liposome is then implanted into the interior of the rabbit's bloodstream through an incision in the chest wall. Once inside, the liposome particles are engulfed in a chemical reaction that dissolves the coagulation protein in the blood. After this, the particles are safely excreted from the animal's body through the excreta.